Most Read Articles
Stephen Padilla, 18 Feb 2020
A wearable, hermetically sealed high-precision vibration sensor enables simultaneous monitoring of multiple health factors associated with the cardiopulmonary system, including heart and respiratory rates, heart sounds, lung sounds, and body motion and position of an individual, a study shows.
Tristan Manalac, 14 Feb 2020
The use of e-cigarettes with flavoured juices for weight-related reasons appears to be common among adolescents, according to a new study.
Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients by 2022 possible.
Pearl Toh, 16 Feb 2019
Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).

Cardiac biomarkers pinpoint CAP patients at high risk of adverse CV events

20 Aug 2019

Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.

Researchers followed 730 hospitalized CAP patients for 1 year. They measured several cardiovascular (proadrenomedullin [proADM], pro b-type natriuretic peptide [proBNP], proendothelin-1, and troponin T) and inflammatory biomarkers (interleukin 6 [IL-6], C-reactive protein [CRP] and procalcitonin [PCT]) at several time points (days 1, 4/5 and 30), exploring their utility for assessing early (within 30 days) or long-term (1 year follow-up) CV events.

A total of 92 patients developed an early CV event and 67 a long-term event. Patients who did vs did not develop CV events had markedly higher initial levels of proADM, proendothelin-1, troponin, proBNP and IL-6. Despite a drop at day 4/5, levels remained quite steady until day 30 in those who developed late events.

On multivariable regression analysis, several days 1 and 30 biomarkers independently predicted CV events, as follows: proendothelin-1 (odds ratio [OR], 2.25, 95 percent CI, 1.34–3.79), proADM (OR, 2.53, 1.53–4.20), proBNP (OR, 2.67, 1.59–4.49) and troponin T (OR, 2.70, 1.62–4.49) for early events, and proendothelin-1 (OR, 3.13, 1.41–7.80), proADM (OR, 2.29, 1.01–5.19) and proBNP (OR, 2.34, 1.01–5.56) for late events.

Furthermore, the addition of IL-6 levels at day 30 to proendothelin-1 or proADM strengthened these cardiac biomarkers’ association with late CV events (ORs, 3.53 and 2.80, respectively).

The findings highlight the usefulness of cardiac biomarkers, potentially aiding personalized treatment optimization and facilitating design of future interventional studies to reduce CV risk, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 18 Feb 2020
A wearable, hermetically sealed high-precision vibration sensor enables simultaneous monitoring of multiple health factors associated with the cardiopulmonary system, including heart and respiratory rates, heart sounds, lung sounds, and body motion and position of an individual, a study shows.
Tristan Manalac, 14 Feb 2020
The use of e-cigarettes with flavoured juices for weight-related reasons appears to be common among adolescents, according to a new study.
Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients by 2022 possible.
Pearl Toh, 16 Feb 2019
Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).